All In Biotech

Drug Trial Radar · NCT01214226

Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis

Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis

Last checked: Nov 20, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 278 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

278

Actual

Start

Dec 2007

Primary completion

Dec 2010

Study completion Jan 2011

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Oct 4, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The treatment of severe forms of alcoholic hepatitis (AH) constitutes a major challenge for clinicians involved in the management of severe alcoholic liver disease. In patients with Maddrey function higher than 32, compelling evidence from data has shown that corticosteroids improve short-term survival. However, novel strategies or molecules are required in light of the fact that approximately 40 % of patients continue to die at 6 months. A double-blinded randomized controlled trial of 101 patients has showed that Pentoxifylline improves survival of patients with severe AH, as compared to placebo. In terms of mechanisms, the effect of pentoxifylline is related to prevention of hepatorenal function whereas corticosteroids induce an early improvement in liver function. When considering these differences of mechanisms, many clinicians suggest that the addition of pentoxyfilline to corticosteroids is an attractive option that needs to be tested in patients with severe AH.

Conditions

  • Alcoholic Hepatitis
  • Alcoholic Liver Disease

Interventions

  • PentoxifyllineDrug

    400 mg prolonged-released tablets 3 time per day for 1 month.

  • placeboDrug

    prolonged-release tablets 3 time per day for 1 month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 6 months

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • University hospital

    Brussels, Belgium

  • University hospital

    Angers, France

  • Centre hospitalier

    Béthune, France

  • Hôpital Jean Verdier (AH-HP)

    Bondy, France

  • University hospital

    Bordeaux, France

  • University hospital

    Caen, France

  • Hospital Antoine Béclère (Assistance Publique des Hôpiaux de Paris)

    Clamart, France

  • Hôpital Beaujon (AH-HP)

    Clichy, France

  • Centre Hospitalier

    Creil, France

  • Hôpital Henri Mondor (AP-HP)

    Créteil, France

  • Centre hospitalier

    Dunkirk, France

  • Centre Hospitalier

    Lens, France

  • University hospital

    Lille, France

  • Centre hospitalier Sambre en avesnois

    Maubeuge, France

  • University hospital

    Montpellier, France

  • University hospital

    Nantes, France

  • University hospital

    Nice, France

  • Hôpital Saint Antoine (AP-HP)

    Paris, France

  • Hôpital de la Pitié-Salpétrière (AP-HP)

    Paris, France

  • Hôpital Cochin (AH-HP)

    Paris, France

  • University hospital

    Poitiers, France

  • University hospital

    Rennes, France

  • Centre Hospitalier Victor Provo

    Roubaix, France

  • University Hospital

    Strasbourg, France

  • Centre Hospitalier

    Tourcoing, France

  • Centre Hospitalier

    Valenciennes, France

  • University hospital, Nancy

    Vandœuvre-lès-Nancy, France

  • Hôpital Paul Brousse (AH-HP)

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.